Every 8-K that ImageneBio, Inc. (IMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc. reported second-quarter 2026 results and updated progress on its lead program, olevaprubart, an OX40-targeting, non-T cell-depleting monoclonal antibody for autoimmune and inflammatory diseases. The Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis is advancing, with patients entering a long-term extension, and a Phase 2 alopecia areata trial is planned.
Following a $30 million PIPE financing in April 2026, the company ended June 30, 2026 with $136.2 million in cash, cash equivalents and marketable securities and expects these resources to fund planned operations into the first quarter of 2028.
For the quarter, research and development expenses were $6.7 million and general and administrative expenses were $5.1 million, for total operating expenses of $11.8 million. Net loss was $10.2 million, or $0.63 per share, compared with $10.7 million, or $4.46 per share, in the 2025 quarter. Total stockholders’ equity was $142,074 (in thousands) as of June 30, 2026.
ImageneBio, Inc. appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer effective July 20, 2026, succeeding CEO Kristin Yarema, Ph.D., in her interim finance role. Grant-Huerta previously held senior finance positions at Atara Biotherapeutics and Amgen.
Under an employment agreement, she receives an annual base salary of $450,000, is eligible for a discretionary annual bonus equal to 40% of base salary, and is granted 65,000 restricted stock units and a stock option for 95,000 shares, each vesting over four years, subject to continued employment. She will participate in ImageneBio’s Severance and Change in Control Plan, which provides 12 months of salary and up to 12 months of health benefits, plus an additional lump sum equal to 100% of target bonus and full equity acceleration upon certain covered terminations during a change in control period. Effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will transition from a full-time executive role to a consulting clinical development and strategic advisory position.
Imagenebio, Inc. reported that Robert Lally, its Senior Vice President of Finance and Operations and principal accounting officer, has resigned. He notified the company on June 22, 2026, and his resignation will be effective July 22, 2026. The company stated that his departure is not due to any disagreement with Imagenebio. Management plans to conduct a search for his replacement.
ImageneBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amended and restated 2025 Equity Incentive Plan that increases the shares of common stock authorized for issuance under the plan by 850,000 shares and adjusts how the automatic annual share reserve increase is calculated.
They also elected two Class II directors, David P. Bonita, M.D. and Joseph P. Slattery, to serve until the 2029 annual meeting, and ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026. There were 11,279,130 shares of voting common stock outstanding as of the April 28, 2026 record date.
ImageneBio, Inc. reported first quarter 2026 results and highlighted progress for its lead OX40 antibody IMG-007 in atopic dermatitis and alopecia areata. License revenue was $0 versus $800,000 a year earlier as the company focuses on clinical development.
Research and development expenses rose to $6.0 million from $4.0 million, and general and administrative expenses increased to $6.1 million from $2.8 million. Net loss widened to $10.6 million from $9.1 million, reflecting higher operating costs.
Imagene ended March 31, 2026 with $117.2 million in cash, cash equivalents, and marketable securities and subsequently completed a $30 million private placement of pre-funded warrants. The company states this financing extends its cash runway into the first quarter of 2028 while it advances the Phase 2b ADAPTIVE trial of IMG-007 in atopic dermatitis and continues development in alopecia areata.
ImageneBio, Inc. entered into a private placement on April 12, 2026, agreeing to sell pre-funded warrants to institutional and accredited investors for approximately $30 million of gross proceeds. The warrants cover up to 5,770,335 shares of common stock at a purchase price of $5.199 per Warrant Share, with a nominal exercise price of $0.001 per share and no expiration until fully exercised.
The warrants include a beneficial ownership cap that prevents any holder from exceeding 19.99% ownership through exercise. In a related Registration Rights Agreement, the company commits to file a resale registration statement for the warrant shares within three business days following August 1, 2026, with cash penalties if it fails to meet certain registration obligations. ImageneBio plans to use the net proceeds, together with existing cash, to support late-phase development readiness in atopic dermatitis and to expand development of its IMG-007 program into additional indications, including alopecia areata.
ImageneBio, Inc. announced that it has agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026. After that date, she will no longer serve as the company’s Principal Accounting Officer and is expected to receive severance benefits under her existing Severance Rights Agreement.
The board of directors has appointed Bob Lally, age 63, currently Senior Vice President, Finance & Operations, to serve as Principal Accounting Officer effective as of the same date. The filing describes Mr. Lally’s prior senior finance and operations roles at Ikena Oncology, Prevail Therapeutics and Arsanis, and notes he did not enter into any new material agreement, has no family relationships with directors or officers, and is not involved in related-party transactions requiring disclosure.
ImageneBio, Inc. reported fourth quarter and full-year 2025 results and highlighted progress on its lead antibody IMG-007, now in the Phase 2b ADAPTIVE trial for moderate-to-severe atopic dermatitis.
For 2025, license revenue was $800 thousand compared with $3.5 million in 2024, reflecting lower collaboration income. Research and development expenses were $28.5 million and general and administrative expenses were $20.7 million, bringing total operating expenses to $49.3 million.
Net loss for 2025 was $45.3 million versus $36.6 million in 2024, as the company invested in building out operations after a reverse merger with Ikena Oncology and incurred transaction-related costs. Imagene ended 2025 with $135.3 million in cash, cash equivalents, and marketable securities, up from $12.1 million a year earlier, supported by the merger and a concurrent $75.0 million private placement.
ImageneBio, Inc. reported that Steven Hui Wang resigned from its Board of Directors, effective immediately on February 12, 2026. The company stated that his resignation was not due to any disagreement with ImageneBio regarding its operations, policies, practices, or strategy. The filing otherwise reflects routine corporate and listing information, including that ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.
Imagenebio, Inc. reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has given notice of her resignation effective December 31, 2025. The company states that Dr. Lu’s decision is not due to any disagreement regarding its operations, policies, or practices, which suggests the change is not driven by internal conflict.
Imagenebio is beginning a search for a new Chief Medical Officer, an important role overseeing its medical and clinical programs. Dr. Lu is expected to provide transition advisory services after her resignation date, helping to maintain continuity in the company’s clinical and medical activities while leadership responsibilities are handed over to her eventual successor.
IMAGENEBIO, INC. (IMA) filed a current report to announce that it has updated its corporate presentation for use in meetings with investors, analysts and other interested parties. The updated presentation, dated November 19, 2025, is being made available on the company’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in this investor presentation and in this report under Item 7.01 is being furnished rather than filed under securities laws, which means it is not automatically incorporated into other securities filings unless specifically referenced there.
ImageneBio, Inc. filed a current report to note that it released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results through a press release dated November 12, 2025, which is included as an exhibit to the report.
The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the federal securities laws. ImageneBio’s common stock trades on The Nasdaq Capital Market under the symbol IMA.
ImageneBio, Inc. expanded its Board of Directors from six to seven and appointed Joseph P. Slattery as a director effective November 1, 2025. He will serve as Chair of the Audit Committee effective November 18, 2025.
The company entered into its standard indemnification agreement with Mr. Slattery in the form previously filed as Exhibit 10.10 to its Form S-1.
Imagenebio, Inc. (IMA) filed an 8-K stating it will not allow its transition services agreement with Miragene Inc. to automatically renew and will instead extend a subset of services for six months after the initial term. The Miragene Extension Services include chemistry, manufacturing and controls, as well as translational sciences research and support. Total fees payable to Miragene for the extension are $200,000, reflecting a limited, short-term continuation of select operational support.
ImageneBio, Inc. appointed its Chief Executive Officer, Kristin Yarema, Ph.D., as the company’s interim principal financial officer, effective immediately on October 21, 2025.
The board made the appointment to fill the finance leadership role on an interim basis. Dr. Yarema’s biographical information is incorporated by reference from the “Management” section of the company’s Form S-1 (File No. 333-290108) filed on September 8, 2025.
ImageneBio, Inc. reported that its Chief Financial Officer and principal financial officer, Jotin Marango, M.D., Ph.D., has submitted his resignation, effective October 20, 2025. The company states that his resignation is not due to any disagreement with the company. ImageneBio plans to conduct a search for a new chief financial officer to fill the role.
ImageneBio amended its current report to provide additional disclosure about the acquired business, Inmagene. The amendment adds Management's Discussion and Analysis for Inmagene and unaudited interim condensed financial statements covering the three- and six-month periods ended June 30, 2025 and 2024. The filing incorporates these items as Exhibits 99.3 and 99.4 and states it does not change any other previously reported items or discuss developments after the original report. The disclosure supplements the Original Report that had reported completion of the Merger.